-+ 0.00%
-+ 0.00%
-+ 0.00%

3 Stocks Giving Public Investors Access to SpaceX Style Private Tech Exposure

Simply Wall St·09/13/2026 09:26:11
語音播報

Vy Capital’s huge bet on SpaceX is rippling across public markets, pulling fresh attention to listed investors that back high‑growth private tech long before an IPO. That kind of capital flow can reshape which stocks benefit most from enthusiasm around frontier businesses and which lag. This article explains how that story relates to three publicly traded crossover investors that appear well exposed to the current SpaceX narrative.

The stocks covered below are only a sample of this crossover theme. The full screen surfaced 26 more publicly listed backers of high growth private tech with equally compelling stories that are not discussed here. To really size up this corner of the market, head straight into the Publicly Listed Backers of High-Growth Private Tech (Crossover & Tech-Focused Asset Managers) screener to identify, filter, and analyze your own highest conviction picks.

Brookfield (TSX:BN)

Overview: Brookfield is a global multi-asset manager that channels capital into large private and growth investments, including technology-focused infrastructure and venture deals.

Operations: Brookfield’s revenue is led by Private Equity at about $28.7b and Infrastructure at $26.2b, with Asset Management contributing $14.4b.

Market Cap: CA$118.2b

Brookfield provides listed access to late stage private and growth capital, from AI factories to energy transition projects, within a diversified real asset platform. The business leans heavily on fee income and global infrastructure exposure, so investor interest in private technology-related assets can affect earnings depending on how one unseen pressure develops.

That pressure point is where the story gets interesting, so spend a minute with the 1 key reward and 3 important warning signs (2 are major!) to see how Brookfield’s tech tilt and risk profile really line up.

TSX:BN Revenue & Expenses Breakdown as at Sep 2026
TSX:BN Revenue & Expenses Breakdown as at Sep 2026

Trinity Capital (TRIN)

Overview: Trinity Capital provides loans and equipment financing to growth stage, often venture backed tech businesses, giving public investors indirect access to late stage private companies.

Operations: Trinity Capital generates about US$313 million of revenue from venture capital style lending activities, all sourced from the United States market.

Market Cap: US$1.7b

For investors tracking how more capital is chasing late stage tech credit since the SpaceX story heated up, Trinity Capital sits right in that slipstream and the current setup shows why this lender is getting more attention from crossover focused portfolios.

"Strong growth in venture debt deal flow, surging assets under management (AUM), and expansion into managed account platforms are fueling investor expectations for sustained double-digit revenue and earnings growth; the rapid pace of origination, however, raises the risk that future credit quality or loan demand could falter if the innovation/startup or venture capital ecosystem weakens unexpectedly."

For Trinity Capital, the real swing factor is what happens if a single funding assumption for late stage tech borrowers quietly starts to shift.

If that funding backdrop really is starting to shift, reading the full narrative for Trinity Capital shows how Trinity Capital’s model could accelerate or stall from here.

NYSE:TRIN Earnings & Revenue Growth as at Sep 2026
NYSE:TRIN Earnings & Revenue Growth as at Sep 2026

IP Group (LSE:IPO)

Overview: IP Group backs early to late stage science and tech businesses, giving public investors access to private and pre IPO growth companies.

Operations: IP Group’s revenue is led by Healthier Future ventures at about £125 million, while other deeptech, cleantech and Oxford Nanopore holdings currently report losses.

Market Cap: £582.2 million

IP Group fits this crossover screen because it channels listed capital directly into late stage tech and science portfolios. These portfolios can re rate sharply when exits arrive.

"The reopening of U.S. IPO and health tech listing activity, illustrated by Hinge Health, is giving IP Group more routes to realise holdings. This directly affects cash generation and the timing of any uplift or crystallisation in earnings from exits."

What happens if one key assumption about how fast external buyers fund these assets quietly shifts will matter a lot for future returns.

If that timing risk is starting to shift for IP Group, the full narrative for IP Group explains where exits could accelerate, stall, or quietly be masking upside.

LSE:IPO Earnings & Revenue History as at Sep 2026
LSE:IPO Earnings & Revenue History as at Sep 2026

Seeking Fresh Alternatives Before They Fly

Market attention moves fast. Breakout themes, fresh momentum, and under the radar stocks can attract the crowd before the most favorable entry points appear. Consider acting sooner rather than later.

  • Spot income workhorses built for staying power and use the 2 dividend fortresses while yields still look attractive and price swings remain in your favour.
  • Track early winners supplying the picks and shovels for AI build out and use the 89 AI infrastructure stocks before the strongest trends are fully reflected in prices.
  • Target portfolio anchors with cleaner balance sheets and use the list of solid balance sheet and fundamentals (7 results) while these resilient operators are still flying under most investors’ radars.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.